We are live on
!
Find out more
Fate Therapeutics
FATE
FATE
164 hedge funds and large institutions have $402M invested in Fate Therapeutics in 2024 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 43 increasing their positions, 59 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
583% more call options, than puts
Call options by funds: $239K | Put options by funds: $35K
0% more capital invested
Capital invested by funds: $401M → $402M (+$482K)
6.66% less ownership
Funds ownership: 107.43% → 100.77% (-6.7%)
10% less funds holding
Funds holding: 182 → 164 (-18)
27% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 59
44% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 36
Holders
164
Holders Change
-18
Holders Change %
-9.89%
% of All Funds
2.35%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
20
Increased
43
Reduced
59
Closed
36
Calls
$239K
Puts
$35K
Net Calls
+$204K
Net Calls Change
+$136K
Top Buyers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$8.03M |
| 2 |
SCM
Superstring Capital Management
New York
|
+$3.77M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.9M |
| 4 |
Goldman Sachs
New York
|
+$1.85M |
| 5 |
BlackRock
New York
|
+$1.39M |
Top Sellers
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$12.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$4.4M |
| 3 |
AG
Artal Group
Luxembourg
|
-$3.39M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.85M |
| 5 |
D.E. Shaw & Co
New York
|
-$2.72M |
